Saridegib is a potent and specific inhibitor of Smoothened (Smo), a key signaling transmembrane protein in the Hedgehog (Hh) pathway.

Evidence from a genetically engineered mouse model of pancreatic cancer demonstrates that Saridegib (IPI-926) can deplete tumor-associated stromal tissue and increase intratumoral mean vessel density. These changes result in enhanced delivery of concurrently administered systemic agents, leading to a decreased tumor burden and prolonged survival in this mouse model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Evidence from a genetically engineered mouse model of pancreatic cancer demonstrates that Saridegib (IPI-926) can deplete tumor-associated stromal tissue and increase intratumoral mean vessel density. These changes result in enhanced delivery of concurrently administered systemic agents, leading to a decreased tumor burden and prolonged survival in this mouse model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Ko AH, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5.  [Content Brief]